In Reply
- PMID: 28280253
- PMCID: PMC5344640
- DOI: 10.1634/theoncologist.2016-0393
In Reply
Abstract
Coriat et al. clarify data about their recently published article on gastroenteropancreatic neuroendocrine carcinomas, specifically as related to the management of grade 3 neuroendocrine tumors.
Comment on
-
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.Oncologist. 2016 Oct;21(10):1191-1199. doi: 10.1634/theoncologist.2015-0476. Epub 2016 Jul 8. Oncologist. 2016. PMID: 27401895 Free PMC article. Review.
-
Gastroenteropancreatic Neuroendocrine Carcinomas: The NET G3 Subcategory Is a Reality.Oncologist. 2017 Mar;22(3):359. doi: 10.1634/theoncologist.2016-0359. Oncologist. 2017. PMID: 28280252 Free PMC article.
References
-
- Pavel M, O'Toole D, Costa F et al. ENETS Consensus Guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016;103:172–185. - PubMed
-
- Fazio N, Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Cancer Treat Rev 2016;50:61–67. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
